Skip to main content
Equibles
EVMN logo

EVMN · Evommune, Inc. · Metrics

Track EVMN — free

Use EVMN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EVMN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.02 -0.60 (-6.96%) At close · Nov 12
Russell 2000 member Rebalance outlook locked
Market Cap
$291.06M
Shares
36.29M
Volume · Nov 12 1.14M Avg daily vol (3M) 810.92K

EVMN metrics

72 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$8.02
Market cap
$291.06M

Price action

23 metrics
Price change (1W)
+42.7%
Price change (30D)
+46.6%
Price change (3M)
-39.0%
Price change (6M)
-63.0%
Price change (YTD)
-49.6%
Price change (1Y)
-55.7%
Trailing year
Price change (5Y)
—
52-week high
$31.57
52-week low
$5.10
Change from 52-week high
-72.7%
Change from 52-week low
+69.0%
Annualized volatility
120.3%
Annualized volatility (3M)
94.0%
Implied volatility (30D)
71.1%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.1
RSI (14D)
68.4
Price vs SMA 50
+11.3%
Price vs SMA 200
-50.1%
Avg volume (3M)
804,050
Relative volume
1.8
Average dollar volume
$6.77M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
36.29M

Valuation

12 metrics
P / E (TTM)
1.6
Trailing earnings · reciprocal yield 64.2%
PEG ratio
—
EV / revenue
11.2×
reciprocal yield 8.9%
EV / EBITDA
—
EV / EBIT
—
P / sales
31.3×
reciprocal yield 3.2%
P / book
1.1
reciprocal yield 88.7%
FCF yield
-23.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-30.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-03-05

Profitability

9 metrics
Gross margin
—
Operating margin
-1,018.9%
Trailing 12 months
Net margin
-946.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$101.89M
Net income (TTM)
−$94.67M
Trailing 12 months
Diluted EPS (TTM)
$5.53
FCF margin
-746.5%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$6.52

Growth

11 metrics
Revenue growth YoY
+85.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$10.00M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2,245.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-34.1%
Return on assets
-31.4%
Debt / equity
0.0
Current ratio
11.7
EBITDA (TTM)
−$101.29M
Free cash flow (TTM)
−$74.65M
Quick ratio
11.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$200.36M
Latest balance sheet
Cash & equivalents
$60.03M
Total assets
$301.95M
Total debt
$434,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$74.15M
Capital expenditures (TTM)
$501,000
R&D (TTM)
$83.77M
SG&A (TTM)
—
Stock compensation (TTM)
$12.81M
R&D / revenue
837.7%
Stock compensation / revenue
128.1%

Ownership (13F)

9 metrics
13F filers
105
13F filer change QoQ
+21
Institutional ownership
98.2%
Conviction holders (share of 13F filers)
4.8%
Crowding (high-turnover and private-fund holders)
68.9%
Private-fund adviser ownership
67.4%
Active holders' share change QoQ
+0.2%
Holder tenure
2.7
Price vs estimated holder cost
-35.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
5.1%

Short interest

3 metrics
Short interest
9.3%
Latest settlement · 3.0 days to cover
Days to cover
3.0d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 2044725 CUSIP 30054Y107 13F (30d) 42 filings 42 filers Visit website Investor relations